{"organizations": [], "uuid": "098879d4bf7611717232986bacb807f7144df18f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180418.html", "section_title": "Archive News &amp; Video for Wednesday, 18 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-us-fda-accepts-supplemental-biolog/brief-u-s-fda-accepts-supplemental-biologics-license-application-for-opdivo-in-previously-treated-patients-with-small-cell-lung-cancer-idUSASC09WCW", "country": "US", "domain_rank": 408, "title": "BRIEF-U.S. FDA Accepts Supplemental Biologics License Application For Opdivo In Previously Treated Patients With Small Cell Lung Cancer", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.976, "site_type": "news", "published": "2018-04-19T04:25:00.000+03:00", "replies_count": 0, "uuid": "098879d4bf7611717232986bacb807f7144df18f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-us-fda-accepts-supplemental-biolog/brief-u-s-fda-accepts-supplemental-biologics-license-application-for-opdivo-in-previously-treated-patients-with-small-cell-lung-cancer-idUSASC09WCW", "ord_in_thread": 0, "title": "BRIEF-U.S. FDA Accepts Supplemental Biologics License Application For Opdivo In Previously Treated Patients With Small Cell Lung Cancer", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters) - bristol-myers squibb co", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 18 (Reuters) - Bristol-Myers Squibb Co:\n* U.S. FOOD AND DRUG ADMINISTRATION ACCEPTS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR OPDIVO (NIVOLUMAB) IN PREVIOUSLY TREATED PATIENTS WITH SMALL CELL LUNG CANCER AND GRANTS PRIORITY REVIEW\n* BRISTOL-MYERS SQUIBB - OPDIVO SUBMISSION BASED ON SAFETY AND EFFICACY DATA FROM SCLC COHORT OF PHASE 1/2 CHECKMATE -032 TRIAL Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-19T04:25:00.000+03:00", "crawled": "2018-04-19T14:58:36.026+03:00", "highlightTitle": ""}